Advances, pharmacological

Pharmacogenetics and Pharmacogenomics (2000) Recent Conceptual and Technical Advances. Pharmacology 61(3) (the entire issue)... 

Interplay of Synthetic Chemistry and Advanced Pharmacology Similar to the demands prompted by rigorous analytical chemistry, the need for syntheses of both anticipated metabolites and experimentally derived metabolite possibilities serves to maintain the complimentary relationship between medicinal chemistry and the biologically oriented disciplines working in the field of drug metabolism and toxicology. This is a valuable relationship where the medicinal chemist... 

Most advances in medicine brought about by chemistry are related to the pharmacological activities of partieular eompounds With perfluorinated liquids, we now have, for the first time, a new class of chemicals that has complete lack of activity as Its mam characteristic of value for biological uses... 

Minotti G, Menna P, Salvatorelli E et al (2004) Anthracyclines molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56 185-229... 

Applications to establish MRLs for new pharmacologically active substances must be submitted to the European Medicines Agency (EMEA) at least 6 months in advance of an application for a marketing authorisation. In order to avoid delays, manufacturers are advised to submit an application once all the necessary data are available, as a product authorisation carmot be granted unless established MRLs are in place. The EMEA should be notified of the intent to submit an application 3 to 4 months in advance of the anticipated date, so that a Rapporteur and Co-Rapporteur can be appointed from among the members of the Committee for Veterinary Medicinal Products (CVMP). 

Before an antiviral agent becomes a drug, advanced toxicity testing, pharmacological combination, and drug-interaction studies are needed. The use of new cell-based assays that can predict mitochondrial toxicity, lactic acidosis, peripheral neuropathy, anemia, hypersensitivity, lipodystrophy, and other potential side effects can alleviate these issues (Stuyver et al. 2002). 

In this chapter, we describe some of the advances in biocomputation that have impacted or potentially will impact pharmaceutical research and development. We list them by biological size, going from the most to the least organized, or from the most complex to the least complex. We focus on clinical sciences in particular, because we feel that simplified, but useful representations of pharmacological interventions have the greatest potential for... 

---